Clinical characteristics and outcomes of psoriasis patients with COVID-19: a retrospective, multicenter cohort study in China

Research Square (Research Square)(2023)

引用 0|浏览4
暂无评分
摘要
Abstract Objective and design Limited information is available on the impact of SARS-CoV-2 infection in psoriasis patients, and we aim to identify clinical factors associated with the prognosis of psoriasis following SARS-CoV-2 infection. Subjects and methods A retrospective, multicenter study was conducted between March and May 2023. Univariable and multivariable logistic regression analysis were employed to identify factors associated with COVID-19-related psoriasis outcomes. A total of 2371 psoriasis patients from 12 clinical centers were included in the study, with 2049 of them being infected with COVID-19. Results Among the infected group, individuals treated with biologics exhibited lower exacerbation rates compared to those receiving traditional systemic or non-systemic treatments (26.7% vs. 39.8% vs. 37.5%, P <0.001). Multivariable logistic regression analysis revealed that psoriasis progression with lesions (adjusted odds ratio[OR]=8.197, 95% confidence interval[CI]=5.685-11.820, compared to no lesions), hypertension (adjusted OR=1.582, 95%CI=1.068-2.343), traditional systemic (adjusted OR=1.887, 95%CI=1.263-2.818), and non-systemic treatment (adjusted OR=1.602, 95%CI=1.117-2.297) were associated with exacerbation of psoriasis after SARS-CoV-2 infection but not biologics (adjusted OR=0.931, 95%CI =0.680-1.274, compared to no treatment). Conclusions Biologics may reduce the risk of psoriasis exacerbation after SARS-CoV-2 infection, compared to traditional systemic and non-systemic treatments. The presence of existing psoriatic lesions and hypertension have been identified as significant risk factors for exacerbation after infection.
更多
查看译文
关键词
psoriasis patients
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要